Patents by Inventor Charles G. Clark

Charles G. Clark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS
    Publication number: 20230250063
    Abstract: The disclosure relates to compounds of formula I, which are formyl peptide 2 (FPR2) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: July 8, 2021
    Publication date: August 10, 2023
    Inventors: James A. Johnson, Zulan Pi, Nicholas R. Wurtz, Joanne M. Smallheer, Meriah Neissel Valente, Ellen K. Kick, Charles G. Clark, Pravin Sudhaka Shirude, Balaji Kumar Seshadri, Amit Kumar Chattopadhyay
  • Triazolopyridine inhibitors of myeloperoxidase and/or EPX
    Patent number: 11008317
    Abstract: The present invention provides compounds of Formula (I); wherein the substituents are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: May 18, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ellen K. Kick, Joanne M. Smallheer, Scott A. Shaw, Benjamin P. Vokits, Andrew K. Dilger, Charles G. Clark, Meriah Neissel Valente, Sutjano Jusuf, Nicholas R. Wurtz
  • TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX
    Publication number: 20200291016
    Abstract: The present invention provides compounds of Formula (I); wherein the substituents are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: March 16, 2017
    Publication date: September 17, 2020
    Inventors: Ellen K. Kick, Joanne M. Smalheer, Scott A. Shaw, Benjiman P. Vokits, Andrew K. Dilger, Charles G. Clark, Meriah Neissel Valente, Sutjano Jusuf, Nicholas R. Wurtz
  • 7-hydroxy-spiropipiperidine indolinyl antagonists of P2Yreceptor
    Patent number: 9428504
    Abstract: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Y1 receptor and may be used as medicaments in the treatment and/or prophylaxis of thromboembolic disorders.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: August 30, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Carl Thibeault, Charles G. Clark, Indawati DeLucca, Carol Hui Hu, Yoon Jeon, Patrick Y. S. Lam, Jennifer X. Qiao, Wu Yang, Yufeng Wang, Tammy C. Wang
  • Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
    Patent number: 9403774
    Abstract: The present invention provides compounds of Formula (I): (Formula (I)) or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: August 2, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Donald J. P. Pinto, Charles G. Clark, Michael J. Orwat, Leon M. Smith, II, William R. Ewing
  • Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
    Patent number: 9315519
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: April 19, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Donald J. P. Pinto, Charles G. Clark, Michael J. Orwat, Leon M. Smith, II, William R. Ewing
  • GUANIDINE AND AMINE SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS
    Publication number: 20150274671
    Abstract: The present invention provides compounds of Formula (I): (Formula (I)) or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.
    Type: Application
    Filed: October 11, 2013
    Publication date: October 1, 2015
    Inventors: Donald J. P. Pinto, Charles G. Clark, Michael J. Orwat, Leon M. Smith II, William R. Ewing
  • GUANIDINE SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS
    Publication number: 20150259358
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.
    Type: Application
    Filed: October 11, 2013
    Publication date: September 17, 2015
    Inventors: Donald J. P. Pinto, Charles G. Clark, Michael J. Orwat, Leon M. Smith, II, William R. Ewing
  • Cyclic P1 linkers as factor XIa inhibitors
    Patent number: 9108981
    Abstract: The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: August 18, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Patrick Y. S. Lam, Charles G. Clark, James R. Corte, William R. Ewing, Paul J. Gilligan, Yoon Jeon, Wu Yang, Leon M. Smith, II, Yufeng Wang
  • 7-HYDROXY-SPIROPIPIPERIDINE INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR
    Publication number: 20150166538
    Abstract: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Y1 receptor and may be used as medicaments in the treatment and/or prophylaxis of thromboembolic disorders.
    Type: Application
    Filed: July 30, 2013
    Publication date: June 18, 2015
    Inventors: Carl Thibeault, Charles G. Clark, Indawati DeLucca, Carol Hui Hu, Yoon Jeon, Patrick Y.S. Lam, Jennifer X. Qiao, Wu Yang, Yufeng Wang, Tammy C. Wang
  • CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS
    Publication number: 20150057262
    Abstract: The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: October 30, 2014
    Publication date: February 26, 2015
    Inventors: Patrick Y.S. Lam, Charles G. Clark, James R. Corte, William R. Ewing, Paul J. Gilligan, Yoon Jeon, Wu Yang, Leon M. Smith, II, Yufeng Wang
  • Cyclic P1 linkers as factor XIa inhibitors
    Patent number: 8901115
    Abstract: The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: December 2, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Patrick Y. S. Lam, Charles G. Clark, James R. Corte, William R. Ewing, Paul J. Gilligan, Yoon Jeon, Wu Yang, Leon M. Smith, II, Yufeng Wang
  • CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS
    Publication number: 20140163002
    Abstract: The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: August 6, 2012
    Publication date: June 12, 2014
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Patrick Y.S. Lam, Charles G. Clark, James R. Corte, William R. Ewing, Paul J. Gilligan, Yoon Jeon, Wu Yang, Leon M. Smith, II, Yufeng Wang
  • Indole antagonists of P2Yreceptor useful in the treatment of thrombotic conditions
    Patent number: 7960569
    Abstract: The present invention provides indole compounds of Formula (I) or (II): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables ring A, X1, X2, X3, X4, R6, and R15 are as defined herein. These compounds are selective inhibitors of the human P2Y1 receptor which can be used as medicaments.
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: June 14, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Patrick Y. S. Lam, Charles G. Clark
  • Urea antagonists of P2Yreceptor useful in the treatment of thrombotic conditions
    Patent number: 7674828
    Abstract: The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.
    Type: Grant
    Filed: May 8, 2008
    Date of Patent: March 9, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Hannguang J. Chao, Huji Tuerdi, Timothy F. Herpin, Jacques Y. Roberge, Yalei Liu, Michael R. Lawrence, Robert P. Rehfuss, Charles G. Clark, Jennifer X. Qiao, Timur Gungor, Patrick Y. S. Lam, Tammy C. Wang, Rejean Ruel, Alexandre L'Heureux, Carl Thibeault, Gilles Bouthillier, Dora M. Schnur
  • UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS
    Publication number: 20080280905
    Abstract: The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.
    Type: Application
    Filed: May 8, 2008
    Publication date: November 13, 2008
    Applicant: Bristol Myers Squibb Company
    Inventors: Hannguang J. Chao, Huji Tuerdi, Timothy F. Herpin, Jaques Yves Roberge, Yalei Liu, R. Michael Lawrence, Robert P. Rehfuss, Charles G. Clark, Jennifer X. Qiao, Timur Gungor, Patrick Y. S. Lam, Tammy Wang, Rejean Ruel, Alexandre L'Heureux, Carl Thibeault, Gilles Bouthillier, Dora M. Schnur
  • INDOLE ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS
    Publication number: 20080221197
    Abstract: The present invention provides indole compounds of Formula (I) or (II): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables ring A, X1, X2, X3, X4, R6, and R15 are as defined herein. These compounds are selective inhibitors of the human P2Y1 receptor which can be used as medicaments.
    Type: Application
    Filed: October 16, 2007
    Publication date: September 11, 2008
    Inventors: Patrick Y.S. Lam, Charles G. Clark
  • Urea antagonists of P2Yreceptor useful in the treatment of thrombotic conditions
    Patent number: 7388021
    Abstract: The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.
    Type: Grant
    Filed: May 10, 2005
    Date of Patent: June 17, 2008
    Assignee: Bristol Myers Squibb Company
    Inventors: Hannguang J. Chao, Huji Tuerdi, Timothy F. Herpin, Jacques Yves Roberge, Yalei Liu, R. Michael Lawrence, Robert P. Rehfuss, Charles G. Clark, Jennifer X. Qiao, Timur Gungor, Patrick Y. S. Lam, Tammy Wang, Rejean Ruel, Alexandre L'Heureux, Carl Thibeault, Gilles Bouthillier, Dora M. Schnur
  • Pyrazolobenzamides and derivatives as factor Xa inhibitors
    Patent number: 7381732
    Abstract: The present application describes pyrazolobenzamides and derivatives thereof of Formula I: P4-P-M-M4I or pharmaceutically acceptable salt forms thereof. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Type: Grant
    Filed: October 24, 2005
    Date of Patent: June 3, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Patrick Y. Lam, Charles G. Clark, Renhua Li, Tasir S. Haque, Karen A. Rossi
  • Guanidine mimics as factor Xa inhibitors
    Patent number: 7235575
    Abstract: The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein rings D-E represent guanidine mimics, which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: August 5, 2005
    Date of Patent: June 26, 2007
    Assignee: Bristol Myers Squibb Company
    Inventors: Patrick Y. Lam, Charles G. Clark, Celia Dominguez, John M. Fevig, Qi Han, Renhua Li, Donald J P Pinto, James R. Pruitt, Mimi L. Quan